AstraZeneca Reports Positive Results for Bladder Cancer Combo Treatment in Phase III Study

03:11 AM EDT, 10/25/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) reported that its late-stage study for its combination treatment for patients with muscle-invasive bladder cancer showed improvement in event-free survival. The British drugmaker said its Volga phase 3 trial, which reviewed Imfinzi with neoadjuvant enfortumab vedotin, reduced the risk of disease progression, recurrence, death, or not undergoing surgery by 49%, according to an Oct. 24 release. AstraZeneca added that the treatment combo lowered the risk of death by 42%, with its safety and tolerability being consistent.